Kentucky Medicaid

Does Kentucky Medicaid cover Wegovy?

Quick answer · Heart Disease Risk Reduction

Kentucky Medicaid covers Wegovy for heart disease risk reduction with prior authorization on Medicaid.

  • Medicaid: Covered with requirements. BMI of 27 or higher

Last verified June 4, 2026. Source: wegovy_pa_criteria_1.3.2026.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Heart Disease Risk Reduction

What Kentucky Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 45 and older
  • BMI of 27 or higher
  • Established cardiovascular disease (MI, stroke, and PAD)
  • On guideline-directed medical therapy (statin, PCSK9_inhibitor, beta_blocker, ACE_inhibitor, ARB, ARNI, and antiplatelet)
  • Lab results confirming eligibility
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

MACE Risk Reduction — Initial Approval

All of:

  • Patient age >= 45 years
  • Being prescribed for MACE risk reduction (cardiovascular death, non-fatal MI, or non-fatal stroke)
  • Documentation within the past year of pre-existing CV disease (prior MI, prior stroke, or symptomatic PAD)
  • BMI >= 27 kg/m²
  • Documentation that medication will be used with reduced calorie diet and increased physical activity
  • Optimization on specified lipid-lowering therapy (moderate-to-high intensity statin or PCSK9 inhibitor) per claims history AND documentation
  • No history of type 2 diabetes
  • Current A1C < 6.5%
  • No NYHA class IV heart failure
  • No end-stage kidney disease or dialysis
  • No plans to undergo coronary, carotid, or peripheral revascularization
  • No personal or family history of MTC or MEN2
  • Not pregnant, breastfeeding, or intending to become pregnant without highly effective contraception
  • Requested dose does not exceed maximum FDA-approved dose
  • Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist

Plus any one of:

  • On beta-blocker
  • On RAS inhibitor (ACE-I, ARB, or ARNI)
  • On antiplatelet therapy (e.g., aspirin, clopidogrel)
  • Prescriber provides medical justification for why patient cannot use lipid-lowering therapies AND beta-blockers, RAS inhibitors, or antiplatelet therapies

Documentation to bring

  • Documentation (e.g., progress note) within the past year confirming pre-existing cardiovascular disease (prior MI, prior stroke, or symptomatic PAD with supporting evidence)
  • Claims history showing optimization on moderate-to-high intensity statin or PCSK9 inhibitor
  • Documentation of concurrent use of beta-blocker, RAS inhibitor (ACE-I/ARB/ARNI), or antiplatelet therapy; OR medical justification for why these cannot be used (with dates of trial if applicable)
  • Baseline BMI documentation (>= 27 kg/m²)
  • Documentation that medication will be used with reduced calorie diet and increased physical activity
  • Current A1C lab result confirming < 6.5%
  • Attestation that patient does not have NYHA class IV heart failure, ESKD/dialysis, planned revascularization, personal/family history of MTC or MEN2

Quantity limits

  • all strengths — pen injector — 4 pens per 28 days
  • all strengths — tablet — 1 tablet per day

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Patient must have at least 5% reduction in baseline body weight OR provider documents assessment of lifestyle and diet interventions if weight loss goal not met. Patient must continue on cardiovascular disease therapy management. Exclusions (no T2DM history, A1C < 6.5%, no NYHA class IV HF, no ESKD/dialysis, no planned revascularization, no MTC/MEN2 history, no pregnancy/breastfeeding) are re-verified at renewal. No re-verification of age >=45, BMI >=27, or documentation of qualifying CV event at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • History of type 2 diabetes
  • Current A1C >= 6.5%
  • NYHA class IV heart failure
  • End-stage kidney disease or dialysis
  • Plans to undergo coronary, carotid, or peripheral revascularization
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Breastfeeding
  • Female of child-bearing potential not using highly effective contraception
  • Concurrent use of another GLP-1 or dual GLP-1/GIP receptor agonist
  • Pregnancy

Policy note: This is a Kentucky Medicaid PA policy administered by MedImpact. The CV qualifying events for PAD include: amputation due to atherosclerotic disease, history of peripheral arterial revascularization, or intermittent claudication with ABI < 0.85 at rest. For stroke, both ischemic and hemorrhagic qualify. GDMT requires optimization on lipid-lowering therapy (statin or PCSK9) as evidenced by claims history, PLUS at least one of: beta-blocker, RAS inhibitor, or antiplatelet; or medical justification for inability to use all three classes. Wegovy tablet is not mentioned as excluded for the CV indication (only excluded for MASH). Copyright 2025 MedImpact Healthcare Systems.

verified June 4, 2026 · source: wegovy_pa_criteria_1.3.2026.pdf

Wegovy for Liver Disease (MASH)

What Kentucky Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 18 and older
  • 6 months of a documented diet and exercise program
  • Prescribed by or in consultation with a specialist
  • Confirmed MASH diagnosis by liver_biopsy, FIB-4, FibroScan_VCTE, and ELF_test, fibrosis stage F2 to F3
  • Lab results confirming eligibility from the last 6 months
  • Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

MASH — Initial Approval

All of:

  • Request is NOT for Wegovy tablet (injection formulation only)
  • Patient age >= 18 years
  • Diagnosis of MASH (also known as NASH) with moderate to advanced liver fibrosis (stages F2 to F3)
  • Prior trial of diet, exercise, and lifestyle modification; patient will continue if approved
  • Prescribed by or in consultation with a gastroenterologist or hepatologist
  • Prescriber attests patient does not have excessive alcohol consumption
  • No history of type 2 diabetes
  • No evidence of cirrhosis
  • No hepatic decompensation
  • No hepatocellular carcinoma (HCC)
  • Not pregnant, breastfeeding, or intending to become pregnant without highly effective contraception
  • Requested dose does not exceed maximum FDA-approved dose
  • Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist

Plus any one of:

  • Liver biopsy within the last 3 years confirming F2-F3 fibrosis
  • FIB-4 index > 2.67 within the last 6 months
  • FIB-4 index 1.3 to 2.67 with sequential VCTE or ELF test within the last 6 months

Documentation to bring

  • Confirmation that request is for injectable Wegovy (not tablet formulation)
  • Documentation of MASH/NASH diagnosis with fibrosis stage F2 or F3, confirmed by one of: liver biopsy within past 3 years, FIB-4 index > 2.67 within past 6 months, or FIB-4 index 1.3–2.67 with VCTE or ELF test within past 6 months
  • Documentation of prior trial of diet, exercise, and lifestyle modification
  • Prescription from or documentation of consultation with a gastroenterologist or hepatologist
  • Prescriber attestation that patient does not have excessive alcohol consumption
  • Attestation that patient does not have history of type 2 diabetes, cirrhosis, hepatic decompensation, or HCC

Quantity limits

  • all strengths — pen injector — 4 pens per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • To renew, the plan looks for Prescriber must submit clinical documentation of clinical benefit compared to baseline, confirmed by at least one of: liver biopsy improvement, reduction in steatohepatitis (NAS score reduction), reduction in liver fibrosis (NASH CRN fibrosis scale reduction), reduction in steatosis, reduction in lobular inflammation, or reduction in ballooning. Exclusions (no T2DM history, no cirrhosis, no hepatic decompensation, no HCC, no pregnancy/breastfeeding) are re-verified at renewal. MASH fibrosis confirmation (biopsy/FIB-4/VCTE/ELF) and specialist requirement are NOT re-verified at renewal.

Not covered when

  • Wegovy tablet formulation is not covered for MASH (injection only)
  • History of type 2 diabetes
  • Evidence of cirrhosis
  • Hepatic decompensation
  • Hepatocellular carcinoma (HCC)
  • Breastfeeding
  • Female of child-bearing potential not using highly effective contraception
  • Concurrent use of another GLP-1 or dual GLP-1/GIP receptor agonist
  • Excessive alcohol consumption
  • Pregnancy

Policy note: This is a Kentucky Medicaid PA policy administered by MedImpact. The MASH indication explicitly excludes the tablet formulation of Wegovy — injection only. Fibrosis confirmation pathways include: (1) liver biopsy within 3 years, (2) standalone FIB-4 > 2.67 within 6 months, or (3) FIB-4 1.3–2.67 combined with VCTE or ELF within 6 months. Specialist (gastroenterologist or hepatologist) prescribing or consultation is required. Alcohol limit is not quantified in grams — policy uses 'excessive alcohol consumption' without specifying a threshold. Copyright 2025 MedImpact Healthcare Systems.

verified June 4, 2026 · source: wegovy_pa_criteria_1.3.2026.pdf

Why Wegovy requests get denied by Kentucky Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. No documented diet and exercise program.
  4. Prescriber isn't the specialist the plan requires.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Kentucky Medicaid cover Wegovy?
Kentucky Medicaid covers Wegovy for heart disease risk reduction with prior authorization on Medicaid.
What BMI do you need for Wegovy under Kentucky Medicaid?
For heart disease risk reduction on Medicaid plans, Kentucky Medicaid requires a BMI of 27 or higher.
How long does a Wegovy approval last with Kentucky Medicaid?
Initial approvals last 6 months, and renewals are granted in 6-month periods.
What does Kentucky Medicaid require to renew Wegovy?
At least 5% weight loss from the starting weight and Patient must have at least 5% reduction in baseline body weight OR provider documents assessment of lifestyle and diet interventions if weight loss goal not met. Patient must continue on cardiovascular disease therapy management. Exclusions (no T2DM history, A1C < 6.5%, no NYHA class IV HF, no ESKD/dialysis, no planned revascularization, no MTC/MEN2 history, no pregnancy/breastfeeding) are re-verified at renewal. No re-verification of age >=45, BMI >=27, or documentation of qualifying CV event at renewal.
How current is this information?
This page reflects Kentucky Medicaid's written policy as of its current version, last verified against the source document on June 4, 2026.

Other medications under Kentucky Medicaid

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes Kentucky Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.